secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-098882
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva VIRAGE Phase 2b: VCN-01+GA OS 10.8mo (HR0.57, p=0.055), PFS 7.0mo (HR0.55, p=0.011)
--------------------------------------------------------------------------------

- In FAS population, VCN-01 + GA improved median OS to 10.8 mo vs 8.6 mo (HR 0.57, p=0.055) and PFS to 7.0 vs 4.6 mo (HR 0.55, p=0.011).
- Patients receiving 2 VCN-01 doses starting GA cycle 4 had OS 14.8 vs 11.6 mo (HR 0.44, p=0.046) and PFS 11.2 vs 7.4 mo (HR 0.48, p=0.017).
- VCN-01 well tolerated; all 13 related serious adverse events resolved; common: flu-like symptoms (13.2%), transaminase increase (5.7%).
- Data to be presented at ESMO 2025 mini oral session on Oct 20; abstract published. Study met primary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/0001104659-25-098882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/tm2528558d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer